This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Female rats needed 1,200 μg intranasal NPY (4x male dose) to prevent SPS-induced depression. Combining 600 μg NPY + DPP4 inhibitor was equally effective.
Why it matters
PTSD and depression disproportionately affect women. Understanding sex-specific dosing of neuropeptide therapies is essential for effective treatment.
The numbers in context
1,200 μg effective (4x male 300 μg); 600 μg alone ineffective; 600 μg + omarigliptin effective; prevented FST depression; tested at 19 days post-SPS
How the study worked
Sprague-Dawley female rats. SPS model. Multiple NPY doses tested intranasally after SPS. Behavioral testing at 19 days: forced swim, elevated plus maze, social interaction. DPP4 inhibitor combination tested.
Who was studied
Sprague-Dawley female rats exposed to single prolonged stress (SPS) PTSD model
What this study cannot tell us
Rat model. SPS may not fully replicate human PTSD. Only one behavioral timepoint tested. Intranasal delivery in rats differs from humans.
Read the original research
Intranasal Neuropeptide Y as a Potential Therapeutic for Depressive Behavior in the Rodent Single Prolonged Stress Model in Females.
Frontiers in behavioral neuroscience, 15, 705579
Citation
Nahvi, Roxanna J; Tanelian, Arax; Nwokafor, Chiso; Hollander, Callie M; Peacock, Lauren; Sabban, Esther L. (2021). Intranasal Neuropeptide Y as a Potential Therapeutic for Depressive Behavior in the Rodent Single Prolonged Stress Model in Females.. Frontiers in behavioral neuroscience, 15, 705579. https://doi.org/10.3389/fnbeh.2021.705579